Abstract CT127: Phase I and expanded access experience of LOXO-195 (BAY 2731954), a selective next-generation TRK inhibitor (TRKi)
Year: 2019
Type: conference-abstract
Source: Clinical Trials
Authors: David Hyman, Shivaani Kummar, Anna Farago, Birgit Geoerger, Morten Mau-Sorensen, Matthew Taylor, Elena Garralda, Ramamoorthy Nagasubramanian, Michael Natheson, Lucy Song, Michael Capra, Mette Jorgensen, Alan Ho, Neerav Shukla, Steve Smith, Xin Huang, Brian Tuch, Nora Ku, Theodore W. Laetsch, Alexander Drilon, David Hong
Institutions: Memorial Sloan Kettering Cancer Center, Stanford Cancer Institute, Stanford University, Massachusetts General Hospital, Institut Gustave Roussy, Fondation Gustave Roussy, Rigshospitalet, Oregon Health & Science University, Vall d'Hebron Hospital Universitari, Nemours Children's Clinic, Dana-Farber Cancer Institute, Kaiser Permanente, Kaiser Permanente Santa Clara Medical Center, Children's Health Ireland at Crumlin, Great Ormond Street Hospital, Great Ormond Street Hospital for Children NHS Foundation Trust, The University of Texas Southwestern Medical Center, The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4235994374